Literature DB >> 24496162

Correlation between hepatitis B surface antigen titers and HBV DNA levels: what about the parameters affecting this correlation?

Ergenekon Karagoz, Alpaslan Tanoglu1, Vedat Turhan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24496162      PMCID: PMC3952425          DOI: 10.4103/1319-3767.126327

Source DB:  PubMed          Journal:  Saudi J Gastroenterol        ISSN: 1319-3767            Impact factor:   2.485


× No keyword cloud information.
Sir, We read the article entitled “Correlation between hepatitis B surface antigen titers and HBV DNA levels” by Alghamdi et al.[1] with interest. The authors concluded that serum HBsAg titers may correlate with HBV DNA in treatment-naïve HBeAg-negative and HBV genotype D patients. Quantitation of HBsAg titer is cheaper than HBV DNA test. Easy availability and inexpensiveness of this parameter may encourage its utilization in clinical practice in the near future. We would like to thank the authors for their contribution. Chronic hepatitis B (CHB) is known to be the leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) in the world. Anti-viral therapy may reduce viral replication. It also leads to biochemical remission, improvement of liver histopathology and reduction of cirrhosis and HCC occurrence.[2] Seroconversion of hepatitis envelope and surface antigen and HBV DNA levels are the tools commonly applied for monitoring the disease and predicting the treatment response.[3] Recent reports have demonstrated that there is a significant correlation between HBsAg titers and intrahepatic HBV DNA and covalently closed circular DNA (ccc DNA) of HBV.[4] This relationship helps the clinician to screen the natural history of HBV infection and predict treatment response in CHB patients.[5] To our knowledge, clinical factors such as age and liver fibrosis are also important parameters in evaluating CHB patients.[5] In our clinical practice, despite low HBsAg titers and HBV DNA levels, liver fibrosis score levels are found to be higher especially in elderly patients. In this context, it would have been better if the authors[1] had compared HBsAg titers according to these parameters. Antiviral therapy may alter HBsAg titers in patients with CHB.[6] So it would have been useful if this patient group was compared with the CHB patients receiving antiviral therapy. Like HBV DNA levels, HBsAg titers may vary in terms of four phases of HBV infection.[7] In this view, it would also be relevant, if the authors[1] evaluate the patient group according to the different phases of HBV infection. In addition, the relationship between HBsAg and HBV DNA in the four phases varies according to the genotype.[5] Therefore, the authors could have compared these patients with other patient groups according to the different genotypes of HBV. We believe that the findings of Alghamdi et al.[1] will lead to further research regarding the association between HBsAg titers and HBV DNA levels. It is important that HBsAg titers be considered along with other independent variables (e.g. age, liver fibrosis) to provide the required information.
  7 in total

1.  HBsAg titers in the different phases of hepatitis B infection in Syrian patients.

Authors:  Nabil Antaki; Negib Zeidane; Nezameldine Alhaj; Milad Hadad; Osama Baroudi; Fadi Antaki; Raed Abouharb; Samir Haffar; Jarir Abdelwahab; Sawsan Alideeb; Fouad Asaad; Ali Aljesri; Daad Doghman; Riad Aaraj; Nazir Ibrahim; Ayman Ali; Marwan Assil; Houda Sabah; Nizar Katranji; Kamel Kebbewar
Journal:  J Clin Virol       Date:  2011-11-13       Impact factor: 3.168

2.  Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.

Authors:  Karsten Wursthorn; Marc Lutgehetmann; Maura Dandri; Tassilo Volz; Peter Buggisch; Bernhard Zollner; Thomas Longerich; Peter Schirmacher; Frauke Metzler; Myrga Zankel; Conrad Fischer; Graeme Currie; Carol Brosgart; Joerg Petersen
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

Review 3.  EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Authors: 
Journal:  J Hepatol       Date:  2008-10-29       Impact factor: 25.083

4.  Clinical implications of the titer of serum hepatitis B surface antigen during the natural history of hepatitis B virus infection.

Authors:  Sang Jun Suh; Song-I Bae; Ji Hoon Kim; Keunhee Kang; Jong Eun Yeon; Kwan Soo Byun
Journal:  J Med Virol       Date:  2013-09-30       Impact factor: 2.327

5.  Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

Authors:  J J Y Sung; K K F Tsoi; V W S Wong; K C T Li; H L Y Chan
Journal:  Aliment Pharmacol Ther       Date:  2008-07-24       Impact factor: 8.171

6.  Quantitative hepatitis B surface antigen titres in Chinese chronic hepatitis B patients over 4 years of entecavir treatment.

Authors:  En-Qiang Chen; Ting-Ting Wang; Lang Bai; Chuan-Min Tao; Tao Liang; Cong Liu; Juan Liao; Hong Tang
Journal:  Antivir Ther       Date:  2013-05-02

7.  Correlation between hepatitis B surface antigen titers and HBV DNA levels.

Authors:  Amal Alghamdi; Nagwa Aref; Malak El-Hazmi; Waleed Al-Hamoudi; Khalid Alswat; Ahmed Helmy; Faisal M Sanai; Ayman A Abdo
Journal:  Saudi J Gastroenterol       Date:  2013 Nov-Dec       Impact factor: 2.485

  7 in total
  2 in total

1.  Clinical Characteristics and Correlation Analysis of Subjects with Chronic Hepatitis B Virus (HBV) Infection and Sustained Low Levels of Hepatitis B Surface Antigen (HBsAg).

Authors:  Jun Cheng; Yuzhu Dai; Li Yan; Huajun Zhou; Xujian Xu; Changgui Sun; Zhongyong Wang
Journal:  Med Sci Monit       Date:  2018-03-29

2.  Clinical characteristics and association analysis of persistent low-level HBsAg expression in a physical examination population with HBV infection.

Authors:  Yuzhu Dai; Feihu Che; Xiaoxiao Jiang; Dawei Cui; Huajun Zhou; Xujian Xu; Changgui Sun; Jun Cheng
Journal:  Exp Ther Med       Date:  2019-11-19       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.